ArticleTranslational lung cancer research2026
Pleural effusion volume as a novel biomarker for prognostic and therapeutic stratification in small cell lung cancer: a translationally-focused cohort study.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Malignant pleural effusion (MPE) in small cell lung cancer (SCLC) is uniformly classified as extensive-stage disease. However, the prognostic heterogeneity based on effusion volume remains uncharacterized, leading to potential overtreatment of low-risk patients. This study aimed to define the distinct prognostic impact of effusion volume and identify survival determinants in the immunotherapy era. Methods: We analyzed 1,026 consecutive SCLC patients treated at Nanjing Jinling Hospital (2008-2024). MPE was cytologically confirmed. Effusion volume was radiographically categorized: small and moderate or greater pleural effusion (PE). The primary outcome was overall survival (OS). Multivariable Cox regression identified independent prognostic factors in the MPE cohort. Results: PE was present in 36.4% (373/1,026) of patients. Cytologically confirmed MPE via an indwelling catheter was identified in 75 patients (7.3%), all of whom had moderate or greater effusions. Strikingly, in the entire cohort stratified by radiographic volume, patients with small PEs had a median OS of 13.8 months, which was statistically indistinguishable from those with no effusion (14.8 months, P=0.54). Both groups fared significantly better than patients with moderate or greater PE (median OS 5.2 months, P<0.001). In the subgroup of cytologically confirmed MPE (n=75, all moderate or greater), multivariable analysis identified Eastern Cooperative Oncology Group performance status (ECOG PS) ≥2 [hazard ratio (HR) =4.64, 95% confidence interval (CI): 1.11-19.39, P=0.03], and elevated serum neuron-specific enolase (s-NSE >45.1 µg/L, HR =4.78, 95% CI: 1.14-19.97, P=0.03) as independent predictors of poor OS. Importantly, immunotherapy use was associated with a profound survival benefit (HR =0.18, 95% CI: 0.04-0.76, P=0.02). Conclusions: MPE in SCLC is a prognostically heterogeneous condition. Effusion volume is a critical stratifier: small PE does not confer worse survival compared to no effusion, whereas moderate or greater PE is a strong independent predictor of poor outcome. Immunotherapy provides a significant survival benefit in MPE patients. These findings position radiographic effusion volume as a practical, clinically actionable biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.